Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Anti-TNF-alpha therapy for ankylosing spondylitis Son JH; Cha SWClin Orthop Surg 2010[Mar]; 2 (1): 28-33BACKGROUND: This review evaluated the safety and efficacy of etanercept in patients with ankylosing spondylitis (AS). METHODS: Of 59 patients with AS, this study reviewed 11 patients who were refractory to conventional therapy and treated with etanercept from September 2005 to January 2008. The mean follow-up duration was 13.6 months. The general improvement was evaluated by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and adverse effects, complications and inflammatory markers were also assessed. RESULTS: The mean BASDAI decreased from 7.1 +/- 1.6 before treatment to 4.2 +/- 1.8 at 3 months after the etanercept treatment (p = 0.001). The mean erythrocyte sedimentation rate and C-reactive protein were decreased significantly by the etanercept treatment. The greatest improvement in symptoms was enthesitis, followed by skin involvement and morning stiffness. There was a significant difference in the improvement in BASDAI along with the follow up duration (p = 0.04). A serious infection was observed as a complication in 1 case. CONCLUSIONS: These results suggest that etanercept can induce significant improvement in most patients with less damage. A trial of tumor necrosis factor inhibition is indicated in all AS patients who do not achieve adequate disease control with disease-modifying antirheumatic drugs, such as methotrexate, leflunomide etc. The patients treated with etanercept should be educated about the possibility of infection and monitored closely.|Adult[MESH]|Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects[MESH]|Antirheumatic Agents/*administration & dosage/adverse effects[MESH]|Blood Sedimentation[MESH]|C-Reactive Protein/analysis[MESH]|Drug Administration Schedule[MESH]|Etanercept[MESH]|Female[MESH]|Humans[MESH]|Immunoglobulin G/*administration & dosage/adverse effects[MESH]|Injections, Subcutaneous[MESH]|Male[MESH]|Middle Aged[MESH]|Receptors, Tumor Necrosis Factor/*administration & dosage[MESH]|Spondylitis, Ankylosing/diagnosis/*drug therapy[MESH]|Tumor Necrosis Factor-alpha/*antagonists & inhibitors[MESH]|Young Adult[MESH] |